ERBB2 and breast cancer: In the neoadjuvant phase II SOLTI-1114 PAMELA trial (NCT01973660), 151 HER2+ BC patients received lapatinib and trastuzumab, plus hormonal therapy if HR+; no significant difference in immune subpopulation densities in TME was observed.